Drugs / SAR421869
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01505062 | Mar 2012 → Aug 2019 | Usher syndrome type 1B, retinitis pigmentosa | Sanofi | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SAR421869 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01505062 ↗ |
| Target | MYO7A | “a recombinant EIAV-based lentiviral vector expressing human MYO7A” PMID 24705452 ↗ Apr 2014 |